Research ArticleArticle
Male Sex Predicts a Favorable Outcome in Early ACPA-Negative Rheumatoid Arthritis: Data From an Observational Study
Giovanni Cagnotto, Lennart T.H. Jacobsson, Emil Rydell, Anna Eberhard, Michele Compagno and Carl Turesson
The Journal of Rheumatology May 2022, jrheum.211199; DOI: https://doi.org/10.3899/jrheum.211199
Giovanni Cagnotto
This work was supported by the Swedish Research Council (grant no. 2015-02228), the Swedish Rheumatism Association (grant no. R-664091), and Lund University (grant no. ALFSKANE-446501). 1G. Cagnotto, MD, Senior Consultant Rheumatologist, A. Eberhard, MD, M. Compagno, MD, PhD, Senior Consultant Rheumatologist, C. Turesson, MD, PhD, Professor, Rheumatology, Department of Clinical Sciences, Lund University, and Department of Rheumatology, Skåne University Hospital, Malmö; 2L.T.H. Jacobsson, MD, PhD, Professor, Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, Gothenburg University, Gothenburg; 3E. Rydell, MD, Rheumatology, Department of Clinical Sciences, Lund University, Malmö, Sweden. LTHJ reports lecture and consulting fees from Novartis, Eli Lilly, and Janssen. MC reports consulting fees from AbbVie and Sanofi Aventis. CT reports consulting fees from Roche; speaking fees from AbbVie, BMS, Nordic Drugs, Pfizer, and Roche; and an unrestricted grant from BMS. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. G. Cagnotto, Reumatologimottagning, Jan Waldenströms gata 1b, Malmö 20502, Sweden. Email: Giovanni.cagnotto@med.lu.se. Accepted for publication April 20, 2022.
Lennart T.H. Jacobsson
This work was supported by the Swedish Research Council (grant no. 2015-02228), the Swedish Rheumatism Association (grant no. R-664091), and Lund University (grant no. ALFSKANE-446501). 1G. Cagnotto, MD, Senior Consultant Rheumatologist, A. Eberhard, MD, M. Compagno, MD, PhD, Senior Consultant Rheumatologist, C. Turesson, MD, PhD, Professor, Rheumatology, Department of Clinical Sciences, Lund University, and Department of Rheumatology, Skåne University Hospital, Malmö; 2L.T.H. Jacobsson, MD, PhD, Professor, Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, Gothenburg University, Gothenburg; 3E. Rydell, MD, Rheumatology, Department of Clinical Sciences, Lund University, Malmö, Sweden. LTHJ reports lecture and consulting fees from Novartis, Eli Lilly, and Janssen. MC reports consulting fees from AbbVie and Sanofi Aventis. CT reports consulting fees from Roche; speaking fees from AbbVie, BMS, Nordic Drugs, Pfizer, and Roche; and an unrestricted grant from BMS. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. G. Cagnotto, Reumatologimottagning, Jan Waldenströms gata 1b, Malmö 20502, Sweden. Email: Giovanni.cagnotto@med.lu.se. Accepted for publication April 20, 2022.
Emil Rydell
This work was supported by the Swedish Research Council (grant no. 2015-02228), the Swedish Rheumatism Association (grant no. R-664091), and Lund University (grant no. ALFSKANE-446501). 1G. Cagnotto, MD, Senior Consultant Rheumatologist, A. Eberhard, MD, M. Compagno, MD, PhD, Senior Consultant Rheumatologist, C. Turesson, MD, PhD, Professor, Rheumatology, Department of Clinical Sciences, Lund University, and Department of Rheumatology, Skåne University Hospital, Malmö; 2L.T.H. Jacobsson, MD, PhD, Professor, Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, Gothenburg University, Gothenburg; 3E. Rydell, MD, Rheumatology, Department of Clinical Sciences, Lund University, Malmö, Sweden. LTHJ reports lecture and consulting fees from Novartis, Eli Lilly, and Janssen. MC reports consulting fees from AbbVie and Sanofi Aventis. CT reports consulting fees from Roche; speaking fees from AbbVie, BMS, Nordic Drugs, Pfizer, and Roche; and an unrestricted grant from BMS. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. G. Cagnotto, Reumatologimottagning, Jan Waldenströms gata 1b, Malmö 20502, Sweden. Email: Giovanni.cagnotto@med.lu.se. Accepted for publication April 20, 2022.
Anna Eberhard
This work was supported by the Swedish Research Council (grant no. 2015-02228), the Swedish Rheumatism Association (grant no. R-664091), and Lund University (grant no. ALFSKANE-446501). 1G. Cagnotto, MD, Senior Consultant Rheumatologist, A. Eberhard, MD, M. Compagno, MD, PhD, Senior Consultant Rheumatologist, C. Turesson, MD, PhD, Professor, Rheumatology, Department of Clinical Sciences, Lund University, and Department of Rheumatology, Skåne University Hospital, Malmö; 2L.T.H. Jacobsson, MD, PhD, Professor, Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, Gothenburg University, Gothenburg; 3E. Rydell, MD, Rheumatology, Department of Clinical Sciences, Lund University, Malmö, Sweden. LTHJ reports lecture and consulting fees from Novartis, Eli Lilly, and Janssen. MC reports consulting fees from AbbVie and Sanofi Aventis. CT reports consulting fees from Roche; speaking fees from AbbVie, BMS, Nordic Drugs, Pfizer, and Roche; and an unrestricted grant from BMS. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. G. Cagnotto, Reumatologimottagning, Jan Waldenströms gata 1b, Malmö 20502, Sweden. Email: Giovanni.cagnotto@med.lu.se. Accepted for publication April 20, 2022.
Michele Compagno
This work was supported by the Swedish Research Council (grant no. 2015-02228), the Swedish Rheumatism Association (grant no. R-664091), and Lund University (grant no. ALFSKANE-446501). 1G. Cagnotto, MD, Senior Consultant Rheumatologist, A. Eberhard, MD, M. Compagno, MD, PhD, Senior Consultant Rheumatologist, C. Turesson, MD, PhD, Professor, Rheumatology, Department of Clinical Sciences, Lund University, and Department of Rheumatology, Skåne University Hospital, Malmö; 2L.T.H. Jacobsson, MD, PhD, Professor, Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, Gothenburg University, Gothenburg; 3E. Rydell, MD, Rheumatology, Department of Clinical Sciences, Lund University, Malmö, Sweden. LTHJ reports lecture and consulting fees from Novartis, Eli Lilly, and Janssen. MC reports consulting fees from AbbVie and Sanofi Aventis. CT reports consulting fees from Roche; speaking fees from AbbVie, BMS, Nordic Drugs, Pfizer, and Roche; and an unrestricted grant from BMS. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. G. Cagnotto, Reumatologimottagning, Jan Waldenströms gata 1b, Malmö 20502, Sweden. Email: Giovanni.cagnotto@med.lu.se. Accepted for publication April 20, 2022.
Carl Turesson
This work was supported by the Swedish Research Council (grant no. 2015-02228), the Swedish Rheumatism Association (grant no. R-664091), and Lund University (grant no. ALFSKANE-446501). 1G. Cagnotto, MD, Senior Consultant Rheumatologist, A. Eberhard, MD, M. Compagno, MD, PhD, Senior Consultant Rheumatologist, C. Turesson, MD, PhD, Professor, Rheumatology, Department of Clinical Sciences, Lund University, and Department of Rheumatology, Skåne University Hospital, Malmö; 2L.T.H. Jacobsson, MD, PhD, Professor, Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, Gothenburg University, Gothenburg; 3E. Rydell, MD, Rheumatology, Department of Clinical Sciences, Lund University, Malmö, Sweden. LTHJ reports lecture and consulting fees from Novartis, Eli Lilly, and Janssen. MC reports consulting fees from AbbVie and Sanofi Aventis. CT reports consulting fees from Roche; speaking fees from AbbVie, BMS, Nordic Drugs, Pfizer, and Roche; and an unrestricted grant from BMS. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. G. Cagnotto, Reumatologimottagning, Jan Waldenströms gata 1b, Malmö 20502, Sweden. Email: Giovanni.cagnotto@med.lu.se. Accepted for publication April 20, 2022.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Male Sex Predicts a Favorable Outcome in Early ACPA-Negative Rheumatoid Arthritis: Data From an Observational Study
Giovanni Cagnotto, Lennart T.H. Jacobsson, Emil Rydell, Anna Eberhard, Michele Compagno, Carl Turesson
The Journal of Rheumatology May 2022, jrheum.211199; DOI: 10.3899/jrheum.211199